What is the optimal management for a 27‑year‑old male with two‑month fever, significant weight loss, recurrent seizures, Glasgow Coma Scale 6/15, persistent leptomeningeal enhancement on MRI, leukocytosis up to 35 × 10⁹/L and procalcitonin 6 ng/mL, who is currently receiving meropenem, vancomycin, dexamethasone, mannitol and empirical four‑drug anti‑tubercular therapy?

Optimal Management of Severe Meningoencephalitis with Suspected Tuberculous Meningitis

Continue the current four-drug anti-tubercular therapy (isoniazid, rifampicin, pyrazinamide, ethambutol) for at least 12 months total duration, maintain dexamethasone tapered over 6-8 weeks, continue meropenem and vancomycin until culture results return, and critically reassess the meropenem given this patient's recurrent seizures and the drug's known seizure-provoking potential.

Anti-Tubercular Therapy

Your empirical ATT initiation was appropriate given the clinical presentation. The ATS/CDC/IDSA guidelines strongly recommend a four-drug regimen (INH, RIF, PZA, EMB) for the initial 2 months, followed by INH and RIF for an additional 7-10 months in tuberculous meningitis 1. For adults with TB meningitis, EMB is preferred as the fourth drug over aminoglycosides 1. The total treatment duration should be 9-12 months minimum, with most experts favoring 12 months given the severity of CNS involvement 1, 2.

Key Monitoring Points:

• Perform repeated lumbar punctures to monitor CSF cell count, glucose, and protein, especially in the first weeks of therapy 1
• The previous CSF showing only 3 cells/µL with normal glucose is atypical for TB meningitis but does not exclude it, particularly if obtained early or after prior antibiotic exposure
• Continue ATT even if initial cultures are negative—culture-negative TB meningitis is common and clinical/radiographic findings justify empirical treatment 1

Corticosteroid Therapy

Your dexamethasone regimen is evidence-based and should be continued with a taper over 6-8 weeks. The ATS/CDC/IDSA guidelines provide a strong recommendation (moderate certainty evidence) for adjunctive corticosteroids in tuberculous meningitis, demonstrating mortality benefit 1. The landmark Vietnamese trial by Thwaites et al. showed dexamethasone reduced mortality (RR 0.69,95% CI 0.52-0.92, P=0.01) in adults with TB meningitis 3. A Cochrane review confirmed this mortality reduction of approximately 25% 4.

The current dose of dexamethasone 8 mg TDS is appropriate. Standard regimens use dexamethasone starting at 8-12 mg daily (or equivalent prednisolone doses), tapered gradually over 6-8 weeks 1, 2.

Critical Reassessment of Meropenem

This is a crucial safety concern: Meropenem carries significant seizure risk, particularly in patients with CNS disorders, history of seizures, or bacterial meningitis 5. The FDA labeling explicitly warns that seizures occur most commonly in patients with "CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis" 5. Your patient has recurrent seizures AND meningoencephalitis—two major risk factors.

Immediate Actions Required:

• Strongly consider switching from meropenem to an alternative broad-spectrum agent (such as cefepime or ceftazidime) that has lower seizure potential once culture sensitivities are available
• If meropenem must be continued, ensure anti-convulsant therapy is optimized and consider dose reduction based on renal function 5
• Critical drug interaction warning: If the patient is on valproic acid for seizure control, meropenem is contraindicated as it dramatically reduces valproic acid levels, increasing breakthrough seizure risk 5

The FDA states: "If focal tremors, myoclonus, or seizures occur, evaluate neurologically, placed on anti-convulsant therapy if not already instituted, and re-examine the dosage of meropenem for injection to determine whether it should be decreased or discontinued" 5.

Vancomycin Considerations

Vancomycin has poor CSF penetration (approximately 7% in one study of ventriculitis patients) 6. While you're using appropriate dosing (1g TDS), recognize that CSF concentrations may be subtherapeutic for CNS infections. Consider:

• TDM-guided dosing to maintain serum levels 20-30 mg/L, which may improve CSF penetration 6
• Vancomycin is reasonable for empirical MRSA coverage but reassess necessity once cultures return

Diagnostic Workup Priorities

While awaiting culture results:

Essential Additional Testing:

• CSF GeneXpert MTB/RIF if not already sent—provides rapid TB diagnosis with rifampicin resistance detection
• CSF adenosine deaminase (ADA) levels—elevated in TB meningitis
• CSF lactate—typically elevated in bacterial/TB meningitis
• Fungal cultures and cryptococcal antigen (given immunosuppression from steroids and severity)
• Repeat imaging if clinical deterioration occurs

Interpreting the Leukocytosis:

The rising TLC (20,000 to 35,000/µL) and procalcitonin 6 ng/mL suggest bacterial infection, but dexamethasone itself causes significant leukocytosis 1. Procalcitonin >2 ng/mL typically indicates bacterial sepsis, supporting continuation of antibacterials until cultures finalize.

Management Algorithm Moving Forward

Days 1-3 (Current Phase):

• Continue all current antimicrobials
• Urgently review seizure medications and meropenem interaction risk
• Await culture results (blood, CSF, urine)
• Repeat CSF analysis to document treatment response

Days 3-7:

• De-escalate antibacterials based on culture results—if cultures remain negative and TB remains primary diagnosis, consider stopping meropenem/vancomycin by day 5-7
• Continue ATT regardless of culture results given clinical syndrome
• Begin dexamethasone taper (typically after 2-3 weeks at full dose)

Weeks 2-8:

• Monitor for TB treatment response: improved consciousness, reduced fever, CSF improvement
• Complete dexamethasone taper over 6-8 weeks total
• Serial lumbar punctures to document CSF normalization
• Monitor for drug-induced hepatotoxicity from ATT

Months 2-12:

• After 2 months of four-drug therapy, transition to INH + RIF for remaining 7-10 months if drug-susceptible TB confirmed or presumed 1
• Continue neurological rehabilitation
• Monitor for hydrocephalus or other complications requiring neurosurgical intervention

Common Pitfalls to Avoid

1. Stopping ATT prematurely if cultures are negative—TB meningitis is frequently culture-negative; treat based on clinical syndrome 1

2. Inadequate corticosteroid duration—the mortality benefit requires the full 6-8 week course 1, 3

3. Ignoring meropenem's seizure risk—this is particularly dangerous in your patient with pre-existing seizures and CNS pathology 5

4. Premature discontinuation of mechanical ventilation—TB meningitis recovery is slow; GCS improvement may take weeks

5. Missing drug-resistant TB—if no improvement after 4-6 weeks, consider MDR-TB and consult infectious disease specialists

Prognosis Considerations

The GCS of 6/15 at presentation indicates severe disease (likely British Medical Research Council Grade III). Even with optimal therapy including corticosteroids, mortality in Grade III TB meningitis approaches 30-50%, and neurological disability is common in survivors 3. The two-month prodrome before severe deterioration is typical for TB meningitis but portends worse outcomes due to treatment delay.

The combination of appropriate ATT, corticosteroids, and supportive care provides the best chance for survival, but prepare the family for prolonged recovery and possible permanent neurological deficits.